Drug Profile
Fibrinogen concentrate - Biotest AG
Alternative Names: BT 524Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Biotest AG
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Afibrinogenaemia
Most Recent Events
- 14 Feb 2024 Grifols announces intention to submit regulatory approval in USA and Europe for Afibrinogenaemia in Q4 of 2024
- 14 Feb 2024 Efficacy and adverse events data from a phase III AdFIrst trial in Afibrinogenaemia released by Grifols
- 02 Oct 2023 Biotest completes a phase III AdFIrst trial in Afibrinogenaemia in Belgium, Germany, Spain, Switzerland, Czech Republic, Poland, and United Kingdom (IV) (NCT03444324)